Attinger-Toller A, Bhindi R, Perlman GY, et al. - Among consecutive patients with severe bicuspid aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with a current generation balloon-expandable valve, researchers analyzed outcomes via clinical and echocardiographic follow-up beyond 1 year. From 6 centers in Europe and Canada, 79 patients who underwent TAVR were analyzed for baseline features, procedural data, 30-day and mid-term clinical follow-up findings. The participants were observed over a median duration of 390 days (interquartile range 138–739 days). The study sample had a mean age of 76 ± 9 years and the median STS risk score for mortality was 3.8% (interquartile range 2.3–5.5%). In 95% of cases, device success was attained. A reduction from 50.2 ± 16.2 to 8.8 ± 4.4 mmHg was noted for postimplantation mean aortic gradient. More than mild aortic regurgitation was not identified in any patient. Overall, findings corroborated the safety and efficacy of treating patients with stenotic bicuspid aortic valves, with favorable valve performance observed over time.